Cargando…

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC). Upon progressive disease, patients normally receive a subsequent ALK TKI. However, when disease progression occurs in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, David, Meier, Urs R., Klaeser, Bernd, Savic, Spasenija, Pless, Miklos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383154/ https://www.ncbi.nlm.nih.gov/pubmed/32774266 http://dx.doi.org/10.1159/000507850

Ejemplares similares

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
por: Weidenbaum, Chloe, et al.
Publicado: (2022)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
por: Minari, Roberta, et al.
Publicado: (2020)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
por: Guisier, F., et al.
Publicado: (2020)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
por: Tan, Daniel S.W., et al.
Publicado: (2020)

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
por: Ortega Sanchez, Guacimara, et al.
Publicado: (2018)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
por: Parker, David, et al.
Publicado: (2014)

Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
por: Duarte, Flávia Amaral, et al.
Publicado: (2021)

Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report
por: McGrath, Mary, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mhff6a2m95kpk5aflt98088bi